Dr. Bishoy M. Faltas on the role of genomic testing in bladder cancer

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.

"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.

Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.

The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.